Howard ‘Jack’ West, MD, Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology and; Therapeutics Research at the City of Hope speaks about ASCO 2021 Highlights in Lung Cancer.
Link to Abstract 8500- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/195950/abstract
Link to Abstract 8503 – Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/195951/abstract
Link to Abstract 9001 – Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.
https://meetinglibrary.asco.org/record/196990/abstract
Link to Abstract 9003 – Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
https://meetinglibrary.asco.org/record/196931/abstract
Link to Abstract 9006 – Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC), and potential biomarkers for response.
https://meetinglibrary.asco.org/record/196820/abstract
Link to Abstract 9007 – Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/196836/abstract
Link to Abstract 9004 – Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.
https://meetinglibrary.asco.org/record/197070/abstract
Link to Abstract 9005 – Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/198284/abstract
Link to Abstract 9013 – Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
https://meetinglibrary.asco.org/record/198410/abstract
Link to Abstract 8517 – Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.